The use of central venous catheters (portacaths) in children with haemophilia.
The experience with central venous implantable devices (portacaths) has been reviewed in children attending the Auckland Hospital Haemophilia Centre. Fourteen children had 23 portacaths inserted. Thirteen had severe Haemophilia A, of whom five had high responding inhibitors to factor VIII. All the children were HIV negative. Ages ranged from 4 months to 13 years at the time of initial placement and 12 were under 5 years. Indications for portacath placement included primary and secondary prophylaxis, induction of immune tolerance, prophylactic therapy post intracranial haemorrhage and poor venous access. Catheter-related infections occurred in 48% of cases. Staphylococcal species were the most common organisms isolated followed by gram-negative bacilli. 63% of the infections were successfully cleared with antibiotics. Haematoma formation occurred in 17% of catheters, primarily in patients who had high factor VIII inhibitor levels. Mechanical problems including blockage, leakage and extrusion of the portacath occurred less frequently (13%). The significant rate of infection in this immunocompetent population is consistent with other reports. Despite the obvious benefits of portacaths this complication is potentially serious and causes appreciable morbidity. In contrast, bleeding complication rates were relatively low.
Bollard
C M
CM
The Auckland Haemophilia Centre, Auckland Hospital, Auckland, New Zealand.
Teague
L R
LR
Berry
E W
EW
Ockelford
P A
PA
D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy / Q000209:etiology; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002408:Catheters, Indwelling / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004866:Equipment Contamination; D004868:Equipment Failure; D005169:Factor VIII / Q000276:immunology; D006406:Hematoma / Q000188:drug therapy / Q000209:etiology; D006467:Hemophilia A / Q000150:complications* / Q000276:immunology / Q000628:therapy*; D002836:Hemophilia B / Q000150:complications / Q000276:immunology / Q000628:therapy; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007223:Infant; D007518:Isoantibodies / Q000009:adverse effects / Q000097:blood; D008297:Male; D013927:Thrombosis / Q000209:etiology / Q000628:therapy; D013997:Time Factors; D014946:Wound Infection / Q000188:drug therapy / Q000209:etiology
D007518:Isoantibodies; D005169:Factor VIII